drugset / Trial / NCT05210582
A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face
NaSingle-groupOpen-labelTreatment
Summary
The CUV104 study will assess the efficacy and safety of afamelanotide in patients with vitiligo on the face and body as a monotherapy in repigmentation.
Timeline
- Start
- 2022-10-11
- Primary completion
- 2023-04
- Completion
- 2023-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afamelanotide | Peptide | — | Subcutaneous |